Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition

Hypertension

Volumn 63, Issue 5, 2014, Pages 951-957

  Devin, Jessica K ^a   Pretorius, Mias ^a   Nian, Hui ^a   Yu, Chang ^a   Billings IV, Frederic T ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4; Hypertension; Norepinephrine; Renin angiotensin system; Vasodilation

Indexed keywords

AMINOPEPTIDASE P; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; ENALAPRILAT; FIBRINOLYTIC AGENT; NORADRENALIN; PLACEBO; SITAGLIPTIN; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENT;

ARTICLE; BRACHIAL ARTERY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; FOREARM BLOOD FLOW; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN EXPERIMENT; MALE; MEAN ARTERIAL PRESSURE; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; VASCULAR RESISTANCE; VASODILATATION;

DIABETES MELLITUS; DIPEPTIDYL PEPTIDASE-4; HYPERTENSION; NOREPINEPHRINE; RENIN-ANGIOTENSIN SYSTEM; VASODILATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BRADYKININ; CROSS-OVER STUDIES; DIPEPTIDYL PEPTIDASE 4; DOUBLE-BLIND METHOD; ENALAPRILAT; ENZYME INHIBITORS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PEPTIDYL-DIPEPTIDASE A; PYRAZINES; SUBSTANCE P; SYMPATHETIC NERVOUS SYSTEM; TRIAZOLES; VASCULAR RESISTANCE;

EID: 84902281059     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02767     Document Type: Article

References (51)

1. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013; 226: 305-314.
2. Herman GA, Stein PP, Thornberry N.A., Wagner JA Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther. 2007; 81: 761-767. (Pubitemid 46625120)
3. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011; 55: 10-16.
4. Benjamin N, Webb DJ The effect of local converting enzyme inhibition on the dilator response to substance P in the human forearm. Br J Clin Pharmacol. 1990; 29: 774-776. (Pubitemid 20183680)
5. Ahmad S, Wang L, Ward PE Dipeptidyl(amino)peptidase IV and amino-peptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther. 1992; 260: 1257-1261.
6. Pesquero JB, Jubilut GN, Lindsey C.J., Paiva AC Bradykinin metabolism pathway in the rat pulmonary circulation. J Hypertens. 1992; 10: 1471-1478. (Pubitemid 23052574)
7. Brown NJ, Gainer JV, Stein C.M., Vaughan DE Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999; 33: 1431-1435. (Pubitemid 29282666)
8. Oliver JJ, Webb DJ, Newby DE Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol. 2005; 25: 2470-2479. (Pubitemid 43732266)
9. Dzurik MV, Diedrich A, Black B., Paranjape SY, Raj SR, Byrne DW, Robertson D. Endogenous substance P modulates human cardiovascular regulation at rest and during orthostatic load. J Appl Physiol (1985). 2007; 102: 2092-2097. (Pubitemid 47080738)
10. Hancock JC, Lindsay GW Pressor and tachycardic responses to intravenous substance P in anesthetized rats. Peptides. 1995; 16: 1439-1445.
11. Hancock JC, Lindsay GW Enhanced ganglionic responses to substance P in spontaneously hypertensive rats. Peptides. 2000; 21: 535-541. (Pubitemid 30261571)
12. Yusuf S, Sleight P, Pogue J., Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-153.
13. Pretorius M, Luther JM, Murphey L.J., Vaughan DE, Brown NJ Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol. 2005; 25: 2435-2440. (Pubitemid 41552667)
14. Marney A, Kunchakarra S, Byrne L., Brown NJ Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010; 56: 728-733.
15. Boschmann M, Engeli S, Dobberstein K., Budziarek P, Strauss A, Boehnke J., Sweep FC, Luft FC, He Y, Foley JE, Jordan J. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009; 94: 846-852.
16. Yamamoto H, Lee CE, Marcus J.N., Williams TD, Overton JM, Lopez ME, Hollenberg A.N., Baggio L., Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002; 110: 43-52. (Pubitemid 34743464)
17. Osaka T, Endo M, Yamakawa M., Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides. 2005; 26: 1623-1631. (Pubitemid 41169757)
18. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol. 2008; 35: 29-34. (Pubitemid 350197677)
19. Saito R, Nonaka S, Konishi H., Takano Y, Shimohigashi Y, Matsumoto H., Ohno M, Kamiya H. Pharmacological properties of the tachykinin receptor subtype in the endothelial cell and vasodilation. Ann N Y Acad Sci. 1991; 632: 457-459.
20. Wharton J, Gulbenkian S, Mulderry P.K., Ghatei MA, McGregor GP, Bloom SR, Polak JM Capsaicin induces a depletion of calcitonin gene-related peptide (CGRP)-immunoreactive nerves in the cardiovascular system of the guinea pig and rat. J Auton Nerv Syst. 1986; 16: 289-309. (Pubitemid 16090542)
21. Furness JB, Costa M, Papka R.E., Della NG, Murphy R. Neuropeptides contained in peripheral cardiovascular nerves. Clin Exp Hypertens A. 1984; 6: 91-106. (Pubitemid 14184493)
22. Fleming BP, Gibbins IL, Morris J.L., Gannon BJ Noradrenergic and pep-tidergic innervation of the extrinsic vessels and microcirculation of the rat cremaster muscle. Microvasc Res. 1989; 38: 255-268. (Pubitemid 20025049)
23. Newby DE, Sciberras DG, Ferro C.J., Gertz BJ, Sommerville D, Majumdar A, Lowry R.C., Webb DJ. Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. Br J Clin Pharmacol. 1999; 48: 336-344. (Pubitemid 29417716)
24. Keeler Jr, Charlton CG, Helke CJ Cardiovascular effects of spinal cord substance P: studies with a stable receptor agonist. J Pharmacol Exp Ther. 1985; 233: 755-760. (Pubitemid 15024445)
25. Krause W, Michael N, Lübke C, Livett B.G., Oehme P. Substance P and epibatidine-evoked catecholamine release from fractionated chromaffin cells. Eur J Pharmacol. 1997; 328: 249-254. (Pubitemid 27263364)
26. Reid AC, Brazin JA, Morrey C, Silver R.B., Levi R. Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system. Curr Pharm Des. 2011; 17: 3744-3752.
27. Smith D, Gilbert M, Owen WG Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985; 66: 835-839. (Pubitemid 15242467)
28. Newby DE, Wright RA, Labinjoh C, Ludlam C.A., Fox KA, Boon NA, Webb DJ Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999; 99: 1411-1415. (Pubitemid 29140904)
29. Labinjoh C, Newby DE, Pellegrini M.P., Johnston NR, Boon NA, Webb DJ Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2001; 38: 1402-1408. (Pubitemid 33033018)
30. Yokosawa H, Endo S, Ohgaki Y., Maeyama J, Ishii S. Hydrolysis of substance P and its analogs by angiotensin-converting enzyme from rat lung. Characterization of endopeptidase activity of the enzyme. J Biochem. 1985; 98: 1293-1299. (Pubitemid 16199239)
31. Wang LH, Ahmad S, Benter I.F., Chow A., Mizutani S, Ward PE Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino) peptidase IV, aminopeptidase M and angiotensin converting enzyme. Peptides. 1991; 12: 1357-1364.
32. Izumi H, Karita K. Axon reflex vasodilatation in human skin measured by a laser Doppler technique. Jpn J Physiol. 1991; 41: 693-702.
33. Wong BJ, Tublitz NJ, Minson CT Neurokinin-1 receptor desensitization to consecutive microdialysis infusions of substance P in human skin. J Physiol. 2005; 568(Pt 3): 1047-1056. (Pubitemid 41646041)
34. McEwan Jr, Benjamin N, Larkin S., Fuller RW, Dollery CT, MacIntyre I. Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms. Circulation. 1988; 77: 1072-1080.
35. Newby DE, Sciberras DG, Mendel C.M., Gertz BJ, Boon NA, Webb DJ Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol. 1997; 43: 493-499. (Pubitemid 27224009)
36. Cappugi P, Tsampau D, Lotti T. Substance P provokes cutaneous erythema and edema through a histamine-independent pathway. Int J Dermatol. 1992; 31: 206-209.
37. Smith CH, Barker JN, Morris R.W., MacDonald DM, Lee TH Neuropeptides induce rapid expression of endothelial cell adhesion molecules and elicit granulocytic infiltration in human skin. J Immunol. 1993; 151: 3274-3282. (Pubitemid 23282640)
38. Ogawa S, Ishiki M, Nako K., Okamura M, Senda M, Mori T., Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011; 223: 133-135.
39. Bosi E, Camisasca RP, Collober C, Rochotte E., Garber AJ Effects of vilda-gliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-895. (Pubitemid 46556583)
40. Shah Z, Pineda C, Kampfrath T., Maiseyeu A, Ying Z, Racoma I., Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, Villamena F, Rajagopalan S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol. 2011; 55: 2-9.
41. Mason RP, Jacob RF, Kubant R, Ciszewski A., Corbalan JJ, Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012; 60: 467-473.
42. Liu L, Liu J, Wong W.T., Tian XY, Lau CW, Wang YX, Xu G, Pu Y., Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a gluca-gon-like peptide 1-dependent mechanism. Hypertension. 2012; 60: 833-841.
43. van Poppel P.C., Netea MG, Smits P, Tack CJ Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011; 34: 2072-2077.
44. Ayaori M, Iwakami N, Uto-Kondo H, Sato H., Sasaki M, Komatsu T, Iizuka M., Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013; 2:e003277.
45. White WB, Cannon CP, Heller S.R., Nissen SE, Bergenstal RM, Bakris GL, Perez A.T., Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-1335.
46. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
47. Braunwald E, Chidsey CA, Pool P.E., Sonnenblick EH, Ross J Jr, Mason DT, Spann JF, Covell JW. Congestive heart failure. Biochemical and physiological considerations. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med. 1966; 64: 904-941.
48. Chidsey CA, Braunwald E. Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev. 1966; 18: 685-700.
49. Bergman AJ, Stevens C, Zhou Y., et al Pharmacokinetic and pharma-codynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006; 28: 55-72. (Pubitemid 43254990)
50. Wang LH, Zhou SX, Li R.C., Zheng LR, Zhu JH, Hu SJ, Sun YL Serum levels of calcitonin gene-related peptide and substance P are decreased in patients with diabetes mellitus and coronary artery disease. J Int Med Res. 2012; 40: 134-140.
51. Fu J, Liu B, Liu P., Liu L, Li G, Wu B., Liu X. Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011; 119: 177-181.